https://abcuro.com/
Home - Abcuro
Jun 3, 2025 - Precision Targeting of Highly Cytotoxic T Cells in Autoimmune Disease.
abcuro
https://abcuro.com/abcuro_people/sundaram-sam/
Sundaram, Sam - Abcuro
sundaramsamabcuro
https://abcuro.com/terms-of-use/
Terms of Use - Abcuro
termsuseabcuro
https://abcuro.com/abcuro_people/greenberg-steven-a-md-ms/
Greenberg, Steven A. - Abcuro
Sep 20, 2023 - Steven A Greenberg, M.D., M.S. is a founder of Abcuro and the Chief Scientific Advisor. Steve is a clinical neurologist at Brigham and Women’s Hospital, and...
greenbergstevenabcuro
https://abcuro.com/abcuro_investors/samsara/
Samsara Biocapital - Abcuro
samsaraabcuro
https://abcuro.com/abcuro_people/karen-tubridy/
Tubridy, Karen - Abcuro
Jun 6, 2025 - Karen Tubridy is the Chief Operating Officer of Abcuro. She brings more than 30 years of experience in drug development strategy and operations supporting...
karenabcuro
https://abcuro.com/about/
About - Abcuro
Apr 30, 2026 - Abcuro is developing ABC008 for autoimmune disorders. ABC008 is a monoclonal antibody designed to selectively deplete highly cytotoxic T cells by targeting...
abcuro
https://abcuro.com/abcuro_people/luk-jeffrey/
Luk, Jeffrey - Abcuro
lukjeffreyabcuro
https://abcuro.com/abcuro_people/wilkins-jeffrey/
Wilkins, Jeffrey - Abcuro
Feb 10, 2025 - Jeffrey Wilkins is the Chief Medical Officer of Abcuro. He is a highly experienced clinician, having advanced clinical programs from IND to regulatory...
wilkinsjeffreyabcuro
https://abcuro.com/privacy-policy/
Privacy Policy - Abcuro
Feb 27, 2023 - Privacy Policy Effective as of June 21, 2022 This Privacy Policy describes the privacy practices of Abcuro, Inc. and our subsidiaries and affiliates...
privacy policyabcuro
https://abcuro.com/abcuro_people/morgan-shelly/
Morgan, Shelly - Abcuro
morganshellyabcuro
https://abcuro.com/abcuro_people/weems-gary/
Weems Gary - Abcuro
weemsgaryabcuro
https://abcuro.com/abcuro_investors/bain-capital-life-sciences/
Bain Capital Life Sciences - Abcuro
bain capital lifesciencesabcuro
https://abcuro.com/pipeline/
Pipeline - Abcuro
Dec 4, 2025 - Abcuro is advancing first-in-class programs in autoimmunity and cancer in which highly cytotoxic immune cells play a foundational role.
pipelineabcuro
https://abcuro.com/abcuro_people/chartienitz-brett/
Chartienitz, Brett - Abcuro
brettabcuro
https://abcuro.com/abcuro_investors/foresite-capital/
Foresite Capital - Abcuro
capitalabcuro
https://abcuro.com/abcuro_investors/eurofarma/
Eurofarma - Abcuro
eurofarmaabcuro
https://abcuro.com/abcuro_people/knowles-julius-jay/
Knowles, Julius (Jay) - Abcuro
Feb 11, 2025 - Jay Knowles joined Mass General Brigham Ventures in 2014 as a Partner. Previously, Jay was Chief Executive Officer of X-BODY Biosciences, which was acquired by...
knowlesjuliusjayabcuro
https://abcuro.com/abcuro_investors/186/
RA Capital - Abcuro
ra capitalabcuro
https://abcuro.com/contact/
Contact - Abcuro
Sep 29, 2025 - 55 Chapel StreetSuite 200Newton, MA 02458
abcuro
https://abcuro.com/abcuro_people/hafler-jason-p-phd/
Hafler, Jason P. , PhD - Abcuro
Feb 10, 2025 - Jason P. Hafler is the Managing Director of Sanofi Ventures. Prior to joining Sanofi in 2014, Jason was the Director of Corporate Development at RaNA...
jasonphdabcuro
https://abcuro.com/abcuro_investors/mass-general-brigham/
Mass General Brigham Ventures - Abcuro
mass general brighamventuresabcuro
https://abcuro.com/abcuro_people/lemessurier-hugo/
LeMessurier, Hugo - Abcuro
hugoabcuro
https://abcuro.com/abcuro_people/shen-yuyi/
Shen, Yuyi - Abcuro
shenyuyiabcuro
https://abcuro.com/abcuro_people/boyce-sarah/
Boyce, Sarah - Abcuro
Jul 30, 2024 - Sarah Boyce joined Avidity as President and Chief Executive Officer and a member of the Board of Directors in October 2019. She has more than 25 years of...
boycesarahabcuro
https://abcuro.com/science/other-publications/
Other Publications - Abcuro
publicationsabcuro
https://abcuro.com/science/publications/
Publications - Abcuro
publicationsabcuro
https://abcuro.com/abcuro_people/hwang-ella/
Hwang, Ella - Abcuro
hwangellaabcuro
https://abcuro.com/abcuro_investors/abrdn/
abrdn - Abcuro
abcuro
https://abcuro.com/abcuro_investors/new-leaf-venture-partners/
New Leaf Venture Partners - Abcuro
new leafventure partnersabcuro
https://abcuro.com/abcuro_people/motschwiller-richard/
Motschwiller, Ricky - Abcuro
rickyabcuro
https://abcuro.com/abcuro_investors/nea/
NEA - Abcuro
neaabcuro
https://abcuro.com/abcuro_people/byrne-donna/
Byrne, Donna - Abcuro
byrnedonnaabcuro
https://abcuro.com/abcuro_people/shah-rajeev/
Shah, Rajeev - Abcuro
Feb 10, 2025 - Rajeev Shah has been a Managing Partner at RA Capital Management since 2004. Raj is active in both public and private investments in companies developing...
shahrajeevabcuro
https://abcuro.com/abcuro_people/ming-fang/
Fang, Ming - Abcuro
Feb 10, 2025 - Ming Fang is a Managing Director at Redmile Group, LLC, a healthcare-focused investment firm. Prior to joining Redmile in 2016, Ming worked in the healthcare...
fangmingabcuro
https://abcuro.com/abcuro_investors/redmile-group-llc/
Redmile Group, LLC - Abcuro
group llcabcuro
https://abcuro.com/abcuro_people/pruzanski-mark/
Pruzanski, Mark - Abcuro
Feb 10, 2025 - Mark Pruzanski is a physician and entrepreneur with more than 30 years of experience in the life sciences. Most recently he served as Chairman and Chief...
markabcuro
https://abcuro.com/abcuro_people/soler-ferran-dulce-phd/
Soler-Ferran, Dulce, PhD - Abcuro
solerferrandulcephdabcuro